CorMedix Inc. To Report First Quarter 2024 Financial Results and Provide a Corporate Update on May 9, 2024

BERKELEY HEIGHTS, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and

GlobeNewswireMay 6 20:30

Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More

Seeking AlphaMay 5 20:00

CorMedix Shares Rise 6% After DefenCath Meets Payment Criteria

By Chris Wack CorMedix shares were up 6% to $5.73 after the company said that the Center for Medicare & Medicaid Services has determined that its DefenCath product meets the criteria for a transition

WSJApr 19 22:50

CorMedix: DefenCath Catheter Lock Solution Is FDA Approved to Reduce Incidence of Catheter-Related Bloodstream Infections in Adult Patients With Kidney Failure >CRMD

CorMedix: DefenCath Catheter Lock Solution Is FDA Approved to Reduce Incidence of Catheter-Related Bloodstream Infections in Adult Patients With Kidney Failure >CRMD

Dow JonesApr 19 20:35

CorMedix: TDAPA Program Provides for Five Years Additional Payment Reimbursement >CRMD

CorMedix: TDAPA Program Provides for Five Years Additional Payment Reimbursement >CRMD

Dow JonesApr 19 20:34

CorMedix DefenCath Meets Transitional Drug Add-On Payment Criteria >CRMD

CorMedix DefenCath Meets Transitional Drug Add-On Payment Criteria >CRMD

Dow JonesApr 19 20:33